NCT06381739 - A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol | Biotech Hunter

Enrollment

350

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

January 31, 2027

Conditions

COVID-19 Infection

Interventions

BIOLOGICAL

ChAd-triCoV/Mac

Clinical-grade, fully certified ChAd-triCoV/Mac produced according to current Good Manufacturing Principles (cGMP) will be provided. A single dose of ChAd-triCoV/Mac diluted in 0.5mL formulated buffer will be aerosolized and inhaled via a mouthpiece and tidal breathing over approximately 2 minutes using the AeroNeb Solo Mesh Nebulizer.

OTHER

Control

A single dose of placebo (0.5mL formulated buffer) will be aerosolized and inhaled as the intervention vaccine.

Trial Locations (1)

L8S 4K1

RECRUITING

Health Sciences Centre, Hamilton

All Listed Sponsors

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

McMaster University

OTHER